Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

An inventory of European data sources for the long-term safety evaluation of methylphenidate.

Murray ML, Insuk S, Banaschewski T, Neubert AC, McCarthy S, Buitelaar JK, Coghill D, Dittmann RW, Konrad K, Panei P, Rosenthal E, Sonuga-Barke EJ, Wong IC.

Eur Child Adolesc Psychiatry. 2013 Oct;22(10):605-18. doi: 10.1007/s00787-013-0386-x. Epub 2013 Mar 19.

2.

Safety of attention-deficit/hyperactivity disorder medications in children: an intensive pharmacosurveillance monitoring study.

Ruggiero S, Rafaniello C, Bravaccio C, Grimaldi G, Granato R, Pascotto A, Sportiello L, Parretta E, Rinaldi B, Panei P, Rossi F, Capuano A.

J Child Adolesc Psychopharmacol. 2012 Dec;22(6):415-22. doi: 10.1089/cap.2012.0003.

PMID:
23234585
3.

A post hoc comparison of the effects of lisdexamfetamine dimesylate and osmotic-release oral system methylphenidate on symptoms of attention-deficit hyperactivity disorder in children and adolescents.

Soutullo C, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Bloomfield R, Squires LA, Coghill DR.

CNS Drugs. 2013 Sep;27(9):743-51. doi: 10.1007/s40263-013-0086-6.

4.

Comorbidities in ADHD children treated with methylphenidate: a database study.

Kraut AA, Langner I, Lindemann C, Banaschewski T, Petermann U, Petermann F, Mikolajczyk RT, Garbe E.

BMC Psychiatry. 2013 Jan 7;13:11. doi: 10.1186/1471-244X-13-11.

5.

Parental reporting of adverse drug reactions associated with attention-deficit hyperactivity disorder (ADHD) medications in children attending specialist paediatric clinics in the UK.

Tobaiqy M, Stewart D, Helms PJ, Williams J, Crum J, Steer C, McLay J.

Drug Saf. 2011 Mar 1;34(3):211-9. doi: 10.2165/11586050-000000000-00000.

PMID:
21332245
6.

Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.

Arcieri R, Germinario EA, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P; Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers.

J Child Adolesc Psychopharmacol. 2012 Dec;22(6):423-431.

PMID:
23362511
7.

Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.

Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

CNS Drugs. 2012 Jul 1;26(7):581-600. doi: 10.2165/11633900-000000000-00000. Review.

PMID:
22712698
8.

[Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].

Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.

Arch Pediatr. 2014 Jan;21(1):108-12. doi: 10.1016/j.arcped.2013.11.001. Epub 2013 Dec 3. French.

PMID:
24309201
9.

European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.

Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L.

Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15.

10.

No elevated genomic damage in children and adolescents with attention deficit/hyperactivity disorder after methylphenidate therapy.

Walitza S, Kämpf K, Artamonov N, Romanos M, Gnana Oli R, Wirth S, Warnke A, Gerlach M, Stopper H.

Toxicol Lett. 2009 Jan 10;184(1):38-43. doi: 10.1016/j.toxlet.2008.10.011. Epub 2008 Oct 28.

PMID:
19015014
12.

Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions.

Gahr M, Freudenmann RW, Hiemke C, Kölle MA, Schönfeldt-Lecuona C.

Psychiatry Res. 2014 Jan 30;215(1):252-4. doi: 10.1016/j.psychres.2013.11.008. Epub 2013 Nov 18.

PMID:
24289907
13.

Guidelines and algorithms for the use of methylphenidate in children with Attention-Deficit/ Hyperactivity Disorder.

Greenhill L, Beyer DH, Finkleson J, Shaffer D, Biederman J, Conners CK, Gillberg C, Huss M, Jensen P, Kennedy JL, Klein R, Rapoport J, Sagvolden T, Spencer T, Swanson JM, Volkow N.

J Atten Disord. 2002;6 Suppl 1:S89-100. Review.

PMID:
12685523
14.

A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents.

King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, Golder S, Taylor E, Drummond M, Riemsma R.

Health Technol Assess. 2006 Jul;10(23):iii-iv, xiii-146. Review.

15.

Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.

Wolff C, Alfred A, Lindermüller A, Rettig K, Mattejat F, Gerwe M, Slawik L, Schäuble B.

Curr Med Res Opin. 2011;27 Suppl 2:35-44. doi: 10.1185/03007995.2011.601733. Epub 2011 Jul 25.

PMID:
21787126
16.

Association of Parkinson's disease with symptoms of attention deficit hyperactivity disorder in childhood.

Walitza S, Melfsen S, Herhaus G, Scheuerpflug P, Warnke A, Müller T, Lange KW, Gerlach M.

J Neural Transm Suppl. 2007;(72):311-5.

PMID:
17982908
17.

One-year prospective follow-up of pharmacological treatment in children with attention-deficit/hyperactivity disorder.

Didoni A, Sequi M, Panei P, Bonati M; Lombardy ADHD Registry Group.

Eur J Clin Pharmacol. 2011 Oct;67(10):1061-7. doi: 10.1007/s00228-011-1050-3. Epub 2011 May 3.

PMID:
21538145
18.

A dose-response study of OROS methylphenidate in children with attention-deficit/hyperactivity disorder.

Stein MA, Sarampote CS, Waldman ID, Robb AS, Conlon C, Pearl PL, Black DO, Seymour KE, Newcorn JH.

Pediatrics. 2003 Nov;112(5):e404.

PMID:
14595084
19.

Safety and tolerability of methylphenidate in preschool children with ADHD.

Wigal T, Greenhill L, Chuang S, McGough J, Vitiello B, Skrobala A, Swanson J, Wigal S, Abikoff H, Kollins S, McCracken J, Riddle M, Posner K, Ghuman J, Davies M, Thorp B, Stehli A.

J Am Acad Child Adolesc Psychiatry. 2006 Nov;45(11):1294-303.

PMID:
17028508
20.

An expert opinion on methylphenidate treatment for attention deficit hyperactivity disorder in pediatric patients with epilepsy.

Baptista-Neto L, Dodds A, Rao S, Whitney J, Torres A, Gonzalez-Heydrich J.

Expert Opin Investig Drugs. 2008 Jan;17(1):77-84. Review.

PMID:
18095920
Items per page

Supplemental Content

Write to the Help Desk